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Abstract The rat Cyclin G1 gene promoter contains one p53-
binding motif upstream of the transcription start site, and a
second motif downstream in the first intron. We have investigated
the possibility that these motifs co-operate to permit high level
promoter activation by p53. Although individual motifs sup-
ported p53-dependent, orientation-independent transcriptional
activation, using reporter plasmids containing both motifs, we
found no evidence for co-operative promoter activation either
after co-transfection with human p53 expression plasmids, or
after exposure of transfected cells to cisplatin and UV-radiation.
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1. Introduction
Many functions of the p53 tumour suppressor protein in-
volve transcriptional activation of target genes (reviewed in
[1]) requiring binding of p53 to a speci¢c motif within the
control regions of these genes [2^5]. Interestingly, the p21/
WAF1 [6], IGFBP3 [7], TGFa [8], EGF receptor [9] and
muscle creatine kinase (MCK) [10] genes contain multiple
copies of this motif within their control regions. Though the
functional signi¢cance of this arrangement is not yet clear,
recent studies of the MCK promoter have suggested that mul-
tiple p53-binding sites may co-operate to allow high level,
p53-dependent transactivation, moreover, this process caused
looping-out of the promoter DNA sequence between the p53-
binding motifs [10^13].
Cyclin G1 is a recently identi¢ed p53 target gene, which is
induced after exposure to UV-radiation [14], Q-radiation [15]
or actinomycin-D [16]. Promoter regions of the mouse, rat
and human genes each possess two motifs with homology to
the consensus p53-binding site [15,17^19]). One is approxi-
mately 250 bp upstream of the transcription start site (pro-
moter p53-binding motif) and separated by about 500 bp from
a second motif downstream and within the ¢rst intron (intron
p53-binding motif). Previous studies have demonstrated that
promoter and intron motifs from the rat gene can bind p53
[20] and that the promoter motif from the mouse and rat
genes supports p53-dependent transactivation [15,21]. It is
likely that the intron p53-binding motif has similar function,
but at present there are no available data which have directly
addressed this notion.
We have investigated the possibility that promoter and in-
tron p53-binding sites from the Cyclin G1 promoter region
may co-operate to permit high level, p53-dependent promoter
activation. We ¢nd that promoter and intron p53-binding
sites from the rat Cyclin G1 promoter region each support
p53-dependent, orientation-independent, transcriptional acti-
vation. However, using reporter plasmids containing both mo-
tifs, we ¢nd no evidence for co-operative promoter activation
either after co-transfection with human p53 expression plas-
mids, or after exposure of transfected cells to UV-radiation
and cisplatin.
2. Materials and methods
2.1. Cell culture, transfection procedure and CAT assay
Mouse L929 ¢broblasts were maintained in Eagle’s modi¢ed essen-
tial medium (EMEM; Gibco BRL, Grand Island, NY) supplemented
with 10% heat-inactivated foetal bovine serum (FBS; Trace Bioscien-
ces, Sydney, Australia) and containing added L-glutamine (2 mM ¢nal
concentration), penicillin/streptomycin (50 U/ml, Gibco, BRL) and
fungizone (2.5 mg/ml, Trace Biosciences). Human bladder cancer cells
UCRU-BL13/0 (BL13; [22]) were maintained in RPMI with the above
supplements.
In each experiment, 5U105 L929 cells seeded into 6 cm petri dishes
were transfected with 6 Wg plasmid DNA and 9 Wl of lipofectamine
reagent (Gibco BRL, Life Technologies Inc., Gaithersburg, MD) as
described by the manufacturers. If the amount of reporter and p53
expression vector DNA was less than 6 Wg, total DNA was main-
tained at 6 Wg by addition of empty CMV vector DNA. The lipid/
DNA complex was removed from cells after 5 h. Cells were harvested
18 h later and levels of CAT activity were measured as described [10].
A similar approach was used in experiments with BL13 cells except
that cells were transfected with 3 Wg total DNA. If the amount of
reporter was less than 3 Wg, total DNA was maintained at 3 Wg by
addition of empty CMV vector DNA. After 24 h, cells were exposed
to 10 Wg/ml cisplatin (cisplatinum (II) diamine dichloride, Sigma
Chemical Company, Sydney, NSW) for 1 h or 100 J/m2 UV-radiation
(wavelength 254 nm using a Stratagene Stratalinker) before harvesting
24 h after treatment.
2.2. Plasmids
Construction of pCMVH6K (empty vector), and both pCMVtag
wtp53 (human wtp53) and pCMVtag 1^323 (human p53 residues 1^
323) which express p53 protein from the human cytomegalovirus early
promoter/enhancer, has been described [13].
Reporter plasmids containing the promoter p53-binding motif from
the rat Cyclin G1 gene were constructed as follows: rat Cyclin G1
promoter region sequences between 3295 to 3225 (P-sequence) rela-
tive to the proposed transcription start site [23], and containing the
promoter p53-binding site between residues 3272 to 3251, were
ampli¢ed by PCR from pGL32-Basic-super Cyclin G-luciferase
(Zauberman, unpublished data) using a 5P primer, 5P-AACCCT-
GCAGCAGGCCAATCTGGCTATTAGCAGCT-3P (Primer 1) and
a 3P primer, 5P-AACCCTGCAGGCTGCGGAACTGAATGTTCA-
ATGCC-3P (Primer 2). After puri¢cation, the fragment was digested
with PstI, puri¢ed and ligated into the unique PstI site within
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p-80MCKCAT [10,24] to form pPromCAT (5P-3P in the Cyclin G1
sequence) or pmorPCAT (3P to 5P in the Cyclin G1 sequence) respec-
tively. Orientation was veri¢ed by restriction enzyme analysis. This
placed the Cyclin G1 promoter p53-binding site immediately 5P to
87 bp of the proximal promoter sequence from the mouse muscle
creatine kinase (MCK) gene. A similar approach was used to generate
pIntronCAT (5P to 3P) and pnortnICAT (3P to 5P) each containing the
intron p53-binding sequence from the rat Cyclin G1 gene. In this case,
promoter sequence between +227 and +294 (I-sequence) containing
the Cyclin G1 intron p53-binding site between residues +249 and
+268 was ampli¢ed using a 5P primer, 5P-AACCCTGCAGCCTCA-
GAGCCCTACACTCCCGAACG-3P (Primer 3) and a 3P primer, 5P-
AACCCTGCAGCGCTCCCACCGCGCCTCTCTAGGAG-3P (Pri-
mer 4).
Plasmids pPICAT and prPICAT containing both rat Cyclin G1
p53-binding motifs separated by 3 kb of p-80MCKCAT vector se-
quence, were generated by inserting the Cyclin G P-sequence into
the unique KpnI site within pIntronCAT. Primers were used as de-
scribed above (Primers 1 and 2) but with KpnI rather than PstI re-
striction enzyme sites incorporated into the ends.
Plasmid pPEIGCAT (containing both rat Cyclin G1 gene p53-bind-
ing sites separated by the normal 500 bp of Cyclin G1 promoter
sequence) was constructed by amplifying promoter sequences between
3295 and +294 using Primers 1 and 4 described above. After PstI
digestion and puri¢cation, the DNA fragment was cloned into the
PstI site within the polylinker sequence of p-80MCKCAT [24].
Correct orientation of this fragment was con¢rmed by restriction
enzyme analysis. A similar approach was used to generate pEIGCAT
(containing promoter sequences between 31 and +294) and pPEG-
CAT (containing promoter sequences between 3295 and +248). For
pEIGCAT, ampli¢cation used a 5P primer, 5P-AACCCTGCAG-
ACCGCACGCTGAACCGGAGGAAGGC-3P and Primer 4 de-
scribed above, whilst for pPEGCAT, Primer 1 from above and a 3P
primer, 5P-AACCCTGCAGTCGGGAGTGTAGGGCTCTGAGGT-
CC-3P were used.
MCK reporter plasmids containing distal and proximal
(pD2800PMCKCAT), proximal only (p2800PMCKCAT), distal
only (pD3300MCKCAT) or no (p2800MCKCAT) p53-binding sites
have been described previously [13].
2.3. PCR conditions
P- and I-sequences were ampli¢ed with a Hybaid Touchdown Ther-
mocycler in a 50 Wl reaction containing 1 Wl template (50 ng/Wl), 1 Wl
each primer (20 pmol/Wl), 4 Wl dNTP mix (25 mM/Wl), 5 Wl 10UDeep-
Vent reaction bu¡er and 0.5 Wl DeepVent enzyme (New England
Biolabs Inc., Beverley, MD). Hotstarting at 94‡C, 1 min before en-
zyme addition then 72‡C, 30 s, was followed by a cycle of 94‡C, 1 min;
60‡C, 30 s; 72‡C, 30 s, and 40 cycles of 94‡C, 1 min; 72‡C, 30 s. A
¢nal step was 72‡C 10 min. Other rat Cyclin G1 promoter region
fragments were ampli¢ed under similar conditions but with reaction
mixtures containing 4 Wl 25 mM MgCl2, the initial annealing temper-
ature was 55‡C, and reactions were held at 94‡C or 72‡C for 30 s or
3.0 min respectively.
3. Results
3.1. Individual p53-binding motifs from the rat Cyclin G1
promoter support transcriptional activation by p53
The rat Cyclin G1 gene promoter region contains two mo-
tifs with homology to the consensus p53-binding sequence
(Fig. 1) which bind p53 with approximately equal a⁄nity
[20]. Promoter sequences between 3295 to 3225 (with the
promoter p53-binding site from residues 3272 to 3251) and
+227 to +294 (with the intron p53-binding site from residues
+249 and +268) were ampli¢ed and cloned in forward (5P-3P,
pPromCAT and pIntronCAT) and reverse (3P-5P, pmorPCAT
and pnortnICAT) orientations into p-80MCKCAT, such that
each motif was upstream and adjacent to a short fragment of
the muscle creatine kinase (MCK) promoter (Fig. 2A). These
plasmids were co-transfected into L929 cells (possessing wild-
type endogenous p53) with either control plasmid
(pCMVH6K), or plasmid expressing wild-type human p53
(pCMVtag wtp53). All reporters having p53-binding motifs
showed transcriptional activation by p53 (Fig. 3), with those
containing the promoter motif activated to a greater extent
than those with the intron motif. Maximal activation (10^
15U for pPromCAT/pmorPCAT, and 3^4U for pIntron-
CAT/pnortnICAT) was seen with 0.5^2 Wg pCMVtag wtp53.
At higher plasmid doses (4^5 Wg), we saw reduced promoter
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Fig. 1. Schematic illustration of the rat Cyclin G1 promoter region
and p53-binding elements. Numbers indicate nucleotide position rel-
ative to the proposed transcription start site [23].
Fig. 2. Schematic illustration of Cyclin G1 (A) and MCK (B) re-
porter plasmids used in this study. Numbers refer to the nucleotide
sequence relative to the transcription start site for each promoter.
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activation, possibly re£ecting sequestration by p53 of protein
factors required for transcription. Without p53-binding motifs
(p-80MCKCAT), p53 had no e¡ect on transcription (Fig. 3).
We conclude that promoter and intron p53-binding motifs
from the rat Cyclin G1 promoter region each mediate wt
human p53-dependent, orientation-independent transactiva-
tion.
3.2. Rat Cyclin G1 p53-binding sites fail to show co-operative
activation
To determine if Cyclin G1 p53-binding sites might co-oper-
ate to permit high level synergistic promoter activation by
p53, reporter plasmids were generated in which promoter
and intron p53-binding motifs were separated by 3.3 kb of
vector sequence (pPICAT and prPICAT; Fig. 2A). Activation
of these promoters by wtp53, or a truncated p53 protein
which is monomeric and shows reduced ability to activate
transcription from individual p53-binding sites (pCMV 1^
323; [13,25]), was then compared to activation of promoters
with individual p53-binding motifs. Chances of detecting co-
operative activation were maximised by using transfection
conditions giving minimal, reproducible activation of pro-
moters with single p53-binding motifs (see Fig. 3). As con-
trols, we used MCK reporter plasmids in which both MCK
p53-binding motifs were present (pD2800PMCKCAT) or
from which either distal (p2800PMCKCAT), proximal
(pD3300MCKCAT) motif or both motifs (p2800MCKCAT)
had been deleted (Fig. 2B; [13]). Results illustrated in Fig. 4A
con¢rmed that in L929 cells, wtp53 induced high level, co-
operative activation of pD2800PMCKCAT (13.5U) com-
pared with p2800PMCKCAT (3.5U) or pD3300MCKCAT
(1.3U). Cyclin G1 reporter plasmids pPICAT and prPICAT
were also activated by wtp53 (Fig. 4B) but rather than high
level induction consistent with co-operation between p53-
binding sites, activation was only 5^6U and similar to that
obtained from promoters with single p53-binding motifs. In
all cases, the truncated p53 protein was less e¡ective than the
wt protein.
In further studies, we obtained similar results even if the
amount of transfected wtp53 plasmid was increased to max-
imum permissible levels (from 0.5 Wg to 5.5 Wg plasmid; data
not shown), suggesting that lack of co-operation was not due
to limiting amounts of transfected p53 protein. In addition,
we were unable to detect co-operative promoter activation in
experiments with monkey CV1 cells which also contain low
levels of endogenous wtp53 and which have been previously
used to demonstrate co-operative activation of the MCK pro-
moter by p53 [25].
3.3. Cyclin G1 promoter sequences between p53-binding motifs
do not permit co-operative promoter activation by p53
Conceivably, the absence of co-operative promoter activa-
tion using pPICAT and prPICAT might have been due to the
absence of normal Cyclin G1 promoter sequences between
p53-binding motifs. To address this possibility, we constructed
reporter plasmids (Fig. 2A) having Cyclin G1 promoter and
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Fig. 3. Individual p53-binding motifs from the Cyclin G1 promoter
region permit p53-dependent, orientation-independent transcriptional
activation. L929 cells were transfected with 1 Wg of each reporter
plasmid and increasing concentrations of pCMVtag wtp53 as de-
scribed in Section 2. Results presented show the mean þ S.E. of at
least three independent experiments.
Fig. 4. Co-operative activation by p53 in promoters with MCK (A)
but not Cyclin G1 (B) p53-binding sites. L929 cells were transfected
with 1 mg of the indicated reporter plasmids and 0.5 Wg of either
pCMVtag wtp53 or pCMVtag 1^323 as described in Section 2. Re-
sults presented show the mean of two (A) or mean þ S.D. of three
(B) independent experiments.
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intron p53-binding motifs separated by the normal 500 bp of
promoter sequence (pPEIGCAT) or from which either the
promoter (pEIGCAT) or the intron (pPEGCAT) motif was
deleted. These plasmids were co-transfected into L929 cells
along with control vector and pCMVtag wtp53. Results
shown in Fig. 5 indicated that pEIGCAT and pPEGCAT
were each activated V4U by wtp53. Consistent with our
results above however, no evidence for co-operative promoter
activation was obtained using pEIGCAT, rather activation
(3.5U) was again similar to that obtained from promoters
with single p53-binding motifs.
Taking these data into consideration with the results de-
scribed in the previous section, we conclude that promoter
and intron p53-binding motifs from the rat Cyclin G1 pro-
moter do not support co-operative promoter activation by
human wtp53.
3.4. Co-operation between Cyclin G1 p53-binding sites does not
occur after exposure to cisplatin or UV-radiation
Cyclin G1 is induced after exposure of cells to UV-radiation
[14], Q-radiation [15] or actinomycin-D [16]. We wished to
determine if co-operative promoter activation involving Cy-
clin G1 p53-binding motifs might require speci¢c cellular con-
ditions induced by DNA damage. In spite of considerable
e¡ort, in initial experiments we were unable to demonstrate
p53-dependent induction of any Cyclin G1 reporter plasmid in
transfected L929 cells exposed to cisplatin or UV. As an alter-
native approach, we used BL13 human bladder cancer cells
which contain wt human p53 [26] and which have been shown
to exhibit increased transcription of a transfected p53-depend-
ent reporter plasmid (pD2800PMCKCAT) after exposure to
cisplatin [27]. We con¢rmed that maximal levels of endoge-
nous p53 induction were achieved by 24 h after exposure of
BL13 cells to either 10 Wg/ml cisplatin or 100 J/m2 UV-radi-
ation (data not shown). The ability of UV and cisplatin to
induce activation of pPEIGCAT, pEIGCAT and pPEGCAT
in transfected cells was then compared. The positive control
for these experiments was pD2800PMCKCAT, which was ac-
tivated by both cisplatin (V6.5U) and UV (V3U) relative to
control, untreated cells (Fig. 6). UV-radiation clearly acti-
vated transcription from all Cyclin G1 reporter plasmids but
the level of activation was similar for all plasmids (V2.5^3U,
Fig. 6). Cisplatin also induced pPEIGCAT and pEIGCAT to
similar levels (V2.5U) but in the absence of the intron-bind-
ing site (pPEGCAT) activation was almost completely abol-
ished.
We conclude that promoter and intron p53-binding motifs
from the rat Cyclin G1 promoter do not support co-operative
promoter activation by human wtp53 after exposure of cells
to cisplatin or UVC.
4. Discussion
Studies using either a model promoter or the MCK gene
promoter have suggested that multiple p53-binding motifs
within p53 target gene promoters may co-operate to permit
high level, synergistic activation by p53 [11^13]. We have ex-
tended these studies to examine the rat Cyclin G1 gene pro-
moter region which also contains two p53-binding motifs
[15,17^19].
Although individual binding sites supported activation of a
heterologous promoter by p53, we were unable to demon-
strate co-operative activation using (i) promoters with p53-
binding motifs separated by heterologous promoter sequences,
(ii) deletion analysis of promoters with motifs separated by
the normal Cyclin G promoter sequence, (iii) promoters where
the relative orientation of each element was inverted. Whilst
we cannot rule out the possibility of promoter sequences out-
side the studied region being required, we suggest that the
simplest explanation for these data is that the two p53-binding
motifs from the Cyclin G promoter region do not co-operate
in p53-dependent promoter activation.
Cyclin G1 is induced after exposure of cells to a variety of
DNA damaging agents [14^16]. In addition, studies of p53
phosphorylation have suggested that di¡erent cellular envi-
ronments have a major in£uence on the response of p53 target
genes, including Cyclin G1, to p53 [21]. As a consequence, we
investigated the possibility that DNA damaging agents might
induce cellular changes which permitted co-operative pro-
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Fig. 6. Cyclin G1 reporter plasmids do not show co-operative pro-
moter activation in response to cisplatin or UV. BL13 cells were
transfected with 3 Wg of pD2800PMCKCAT or 2 Wg of Cyclin G1
reporter plasmids and exposed to 10 Wg/ml cisplatin or 100 J/m2
UV as detailed in Section 2. Results presented show the mean of
two (UV) or mean þ S.D. of three (cisplatin) independent experi-
ments.
Fig. 5. Absence of p53-dependent, co-operative promoter activation
by deletion analysis of Cyclin G1 reporter plasmids. L929 cells were
transfected with 2 Wg of each reporter plasmid and 2.0 Wg of
pCMVtag wtp53 as described in Section 2. Results presented show
the mean þ S.D. of three independent experiments.
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moter activation involving Cyclin G1 p53-binding motifs.
However, though able to show modest promoter activation
after exposing transfected cells to both cisplatin and UV, we
failed to observe high level, co-operative promoter activation
after treatment with either agent.
The two p53-binding motifs in the Cyclin G1 promoter are
conserved between human, rat and mouse genes [19], suggest-
ing that this organisation is functionally important. If not
involved in co-operative promoter activation by p53, then
how might two di¡erent p53-binding motifs contribute to reg-
ulation of Cyclin G1 expression by p53? Although the motifs
bind p53 with equal a⁄nity [20], one possibility is that each
may respond di¡erently to p53. Consistent with this notion, in
transfection experiments, we observed that the promoter motif
clearly permitted greater transcriptional activation of a heter-
ologous promoter than the intron motif, and obtained some
preliminary data to suggest that the intron motif is responsible
for the ability of UV to induce promoter activation. More-
over, in a recent study with reporter plasmids containing ei-
ther both motifs or the promoter motif only, Lohrum and
Scheitmann provided evidence that the intron motif was re-
sponsible for the repression of Cyclin G1 promoter activity
after okadaic acid-induced hyperphosphorylation of p53 [21].
At present, however, information on the biological role of
Cyclin G1 is limited. As a consequence, the physiological basis
for activation of the Cyclin G1 gene by p53 is not clear and
the functional importance of two p53-binding sites within the
promoter region remains to be determined.
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